EGFR and lung adenocarcinoma: Of the 11 patients with lung adenocarcinoma (LUAD), 6 (54.6%) had at least one actionable mutation, of which 3 (27.3%) were with EGFR mutations, 3 (27.3%) showed KRAS mutations, and none were with BRAF mutations.